AVKARE Ranitidine Tablets, USP 300 mg Rx Only NDC Manufactured for: AvKARE, Inc. Pulaski, TN 3847...
FDA Drug Recall #D-0525-2020 — Class II — November 14, 2019
Recall Summary
| Recall Number | D-0525-2020 |
| Classification | Class II — Moderate risk |
| Date Initiated | November 14, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | AVKARE Inc. |
| Location | Pulaski, TN |
| Product Type | Drugs |
| Quantity | 104,797 bottles |
Product Description
AVKARE Ranitidine Tablets, USP 300 mg Rx Only NDC Manufactured for: AvKARE, Inc. Pulaski, TN 38478 a) 250 tablets NDC 42291-725-25; b) 30 tablets NDC 42291-725-30
Reason for Recall
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Distribution Pattern
Nationwide.
Lot / Code Information
Lots: a) 21307 Exp. 02/29/2020, 21309 Exp. 02/29/2020, 21528 Exp. 02/29/2020, 21527 Exp. 02/29/2020, 22247 Exp. 06/30/2020, 23214 Exp. 09/30/2020, 23243 Exp. 09/30/2020, 23244 Exp. 11/30/2020, 24198 Exp. 01/31/2021, 24199 Exp. 01/31/2021, 24289 Exp. 01/31/2021; b) 22291 Exp. 06/30/2020, 23215 Exp. 09/30/2020, 23776 Exp. 01/31/2021
Other Recalls from AVKARE Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1329-2022 | Class III | Lamotrigine Tablets, USP 100 mg, 1000-count bot... | Jul 20, 2022 |
| D-0631-2021 | Class III | Phytonadione Tablets 5 mg, Rx Only, 30 Tablets ... | Jun 9, 2021 |
| D-0168-2021 | Class I | TraZODONE Hydrochloride Tablets USP 100 mg, Rx ... | Dec 7, 2020 |
| D-0167-2021 | Class II | Sildenafil Tablets USP 100 mg, Rx Only, 100-cou... | Dec 7, 2020 |
| D-0070-2021 | Class II | Mesalamine Delayed-Release Tablets, USP 1.2 gra... | Oct 30, 2020 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.